Australia's most trusted
source of pharma news
Monday, 15 September 2025
Posted 12 September 2025 PM
Novo Nordisk has been buckling under fierce competition in the obesity and diabetes space and news it had decided to overhaul its operations - including significant job cuts - was our top story this week.
Under new leadership, Novo is transforming into a leaner, faster, performance-driven company. The aim is to reallocate significant savings into areas that matter, such as new commercial execution strategies, ramping up manufacturing and pursuing more R&D.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.